SCHEMBL3134094

SCHEMBL3134094

COc1ccc(-c2csc(N)n2)cc1[N+](=O)[O-]

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.72
SMN1; SMN2 Q16637 7/20 0.72
NPC1 O15118 6/20 0.72
RAB9A P51151 6/20 0.72
LMNA P02545 3/20 0.72
RECQL P46063 1/20 0.72
ALDH1A1 P00352 8/20 0.71
KMT2A Q03164 5/20 0.71
MEN1 O00255 4/20 0.71
POLB P06746 2/20 0.71
MAPK1 P28482 2/20 0.71
NFKB1 P19838 2/20 0.71
NFKB2 Q00653 2/20 0.71
RELA Q04206 2/20 0.71
HTT P42858 2/20 0.53
GAA P10253 1/20 0.53
PDGFRB P09619 1/20 0.51
PDGFRA P16234 1/20 0.51
KDM4E B2RXH2 2/20 0.48
TUBB4A P04350 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31084656 1.00 MAPT (0.72) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL25239669 0.86 MAPT (0.81) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL7369499 0.82 MAPT (0.54) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL3593375 0.81 MEN1 (0.57) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL427925 0.80 MEN1 (0.75) MAPTSMN1; SMN2NPC1RAB9ARECQL
SCHEMBL8357836 0.80 MAPT (0.59) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL25279844 0.80 RAB9A (0.59) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL12190708 0.79 RAB9A (0.59) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL25288808 0.79 RAB9A (0.73) MAPTSMN1; SMN2NPC1RAB9ALMNA
Bromide SCHEMBL8360766 0.79 NPC1 (0.73) MAPTSMN1; SMN2NPC1RAB9ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353821-A1 BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS INST NAT SANTE RECH MED (FR) 2025-11-20 US disclosed
EP-4452956-A1 BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2024-10-30 EP disclosed
WO-2023118373-A1 BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2023-06-29 WO disclosed
EP-4201928-A1 BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2023-06-28 EP disclosed
US-8785499-B2 Targeting NAD biosynthesis in bacterial pathogens UNIVERSITY OF MARYLAND, BALTIMORE (US) 2014-07-22 US disclosed
US-20120190708-A1 TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS UNIVERSITY OF MARYLAND, BALTIMORE (US) 2012-07-26 US disclosed
US-20100004441-A1 N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds SCHMITZ FRANZ ULRICH 2010-01-07 US disclosed
US-7595398-B2 N-(5-membered aromatic ring)-amido anti-viral compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-09-29 US disclosed
EP-1971597-A2 N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. (US) 2008-09-24 EP disclosed
WO-2007070600-A2 N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353821-A1 BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS HSPA5, HSP90B1, BAD MAPT 2506/4885SMN1; SMN2 2588/4885NPC1 2223/4885
US-20120190708-A1 TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS NAMPT, NAPRT, NADK MAPT 1896/4885SMN1; SMN2 4145/4885NPC1 992/4885
US-20100004441-A1 N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds ZC3HAV1, ZC3HAV1L, HAVCR2 MAPT 1615/4885SMN1; SMN2 1431/4885NPC1 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.